Recalls & Warnings August 31, 2012 Energy, Fat Loss Supplement Recalled For Ephedrine Alkaloids On August 28, 2012, dietary supplement re-sale distributor Brand New Energy (BNE) issued a recall of EphBurn 25 after FDA testing found the product to contain ephedrine alkaloids
October 9 Product: Zealand Pharmas dasiglucagon Indication: Congenital hyperinsulinism Timing is everything, if youre Zealand Pharma

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry GLP-1 analogues do not increase thyroid cancer risk, suggests BMJ study Drugs known as GLP-1 analogues have become increasingly popular to treat diabetes and obesity, but there have been concerns that they might increase the risk of thyroid cancer

Many modern diets suppress natural GLP-1 activity
Health care providers and patients must be well-informed of these risks, and patients with a personal or family history of medullary thyroid carcinoma or patients with Multiple Endocrine Neoplasia syndrome type 2 should not use tirzepatide
882-P: Eloralintide, a selective, long-acting amylin receptor agonist for obesityphase 1 proof of concept